Protein in Medical Technology

In Rare Disorder, a Familiar Protein Disrupts Gene Function

-Knowledge May Improve Diagnosis for Children with Cornelia deLange Syndrome- PHILADELPHIA, May 27 /PRNewswire-USNewswire/ -- An international team of scientists studying a rare genetic disease discovered that a bundle of proteins with the long-established function of keeping chromo...

Key Protein May Lead to Faster Acting Anti-Depression Drugs

NEW YORK, March 23 /PRNewswire-USNewswire/ -- Research conducted by Nobel laureate Paul Greengard, Medical Director of The Michael Stern Parkinson's Research Center at The Rockefeller University , Dr. Jennifer L. Warner-Schmidt in New York and colleagues in Sweden, demonstrated in the Journal o...

Bone Biologics Announces Significant Milestone for Spinal Fusion Surgery Using Recombinant Protein and Demineralized Bone Matrix

Primate trials validate efficacy of the process THOUSAND OAKS, Calif., Feb. 24 /PRNewswire/ -- Bone Biologics, Inc. announced today that it has successfully completed the initial primate trials validating the efficacy of the proprietary bone growth regeneration UCB-1 (NELL-1) protein in spina...

The First Direct Structural Evidence of SV2A has Been Revealed Thanks to Protein Tomography(TM), and Published in BBRC

Summary: Protein Tomography(TM) has yet Again Provided Structural Proof of a Drug Target Function. A Study Performed by Sidec and UCB, Characterizes the Target of Anti-Epileptic Drug in Situ Where Two Major Conformations Have Been Identified STOCKHOLM, September 9 /P...

Phase II Data on Lilly's Antibody Show It Affects Amyloid Beta, a Protein Believed To Be Associated with Alzheimer's Disease

Findings lead to decision to start Phase III pivotal study of LY2062430 in 2009 CHICAGO, July 30 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) today announced interim results of its Phase II study of LY2062430, an investigational anti-amyloid beta ...

Arriva Pharmaceuticals Moves Forward to Phase 2b Development of Lead Inhaled Protein rAAT Replacement Therapy for Hereditary Emphysema

Nordic Biotech II K/S and MPM BioVentures close on additional $6 million investment on top of $75 million previous investment AMSTERDAM, Netherlands and ALAMEDA, Calif., Feb. 28 /PRNewswire/ -- Arriva Pharmaceuticals, a biopharmaceutical company focused on developing anti- inflammator...

NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the GTCbio Cancer Drugs Research & Development Conference

NEW YORK, Feb. 22 /PRNewswire/ -- NexGenix Pharmaceuticals, presented data on its Hsp90 inhibitor program today at the GTCBio 5th Annual Cancer Drugs Research & Development Conference taking place in Phoenix, Arizona. The company presented data on NXD30001, one of several novel, radicicol-base...

Fundamental Applied Biology, Inc. Is Awarded SBIR Phase IIB Grant for the Commercialization of Protein Therapeutics Using Cell Free Technology

MENLO PARK, Calif., Jan. 16 /PRNewswire/ -- Fundamental Applied Biology, Inc. (FAB) announced today that it has been awarded a Small Business Innovative Research (SBIR) Phase IIB grant from the National Science Foundation. The $500,000 grant will be used to continue to develop FAB's cell-free ...

VioQuest Pharmaceuticals Announces Dosing of First Patient in Phase IIa Solid Tumor Study for Lenocta(TM), a Novel Protein Tyrosine Phosphatase Inhibitor

BASKING RIDGE, N.J., Nov. 26 /PRNewswire-FirstCall/ -- VioQuest Pharmaceuticals (OTC Bulletin Board: VQPH) today announced the initiation of a Phase IIa study of Lenocta(TM) (sodium stibogluconate), a novel protein tyrosine phosphatase inhibitor, in combination with interferon alpha, an immune...

The New England Journal of Medicine Publishes First Clinical Results for MedImmune's Chitinase-like Protein YKL-40 in Patients With Asthma

- Findings Suggest Protein May Play an Important Role in the Pathobiology of Severe Asthma, Identify Potential New Biomarker for Severity of Disease - GAITHERSBURG, Md., Nov. 14 /PRNewswire/ -- MedImmune, Inc. today announced the publication of the first clini...

First High-Res 3-D Structures of Mammalian HSP90 Protein Solved, Key to Better Targets for AIDS, Sepsis, Cancer Drugs

HWI Scientist Dr. Dan Gewirth's Groundbreaking Research Makes Cover of Molecular Cell BUFFALO, N.Y., Oct. 19 /PRNewswire/ -- Dr. Dan Gewirth, Hauptman-Woodward senior research scientist, has just solved the structure of the first mammalian GRP94 protein implicated ...

Study Suggests Soy Protein May Reduce Prostate Cancer Risk

ST. LOUIS, Oct. 4 /PRNewswire/ -- A study published in the Oct. 1 Journal of Nutrition suggests consumption of soy protein may play a role in reducing the risk of prostate cancer, Solae notes, giving consumers another healthy reason to make soy part of their diet. The study, "Soy protein isol...

Study Published in Endocrinology Reports Potential of Modigene Technology to Extend Duration of Protein Drugs

- Publication in Leading Peer-Reviewed Journal Represents Further Scientific Validation of the Potential Utility of Modigene's CTP Technology - VIENNA, Va., Sept. 24 /PRNewswire-FirstCall/ -- Modigene Inc. (OTC Bulletin Board: MODG) today reported that rese...

Nostrum Announces the Successful Completion of Early Proof-of-Concept Study for its Novel Clot Busting Therapeutic Protein

EDISON, N.J., April 21 /PRNewswire/ -- Nostrum, a privately-held company based in Edison, New Jersey, announced today that it has successfully completed its early, primate, proof-of-concept study for its novel thrombolytic clot-buster protein currently known as SMRX11. Nostrum's Symmetrix subs...

CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein

VIENNA, Va., Sept. 19 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (Amex: CVM ) announces that its CEL-1000 immunomodulator was shown to be able to jump start the immune response against the recombinant hepatitis B virus protein more quickly than did other vaccine adjuvants. This effect in t...

Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate

FREISING-WEIHENSTEPHAN, Germany, July 10, 2007 /PRNewswire/ -- Pieris AG, a bio-pharmaceutical company developing Anticalins(R), a novel class of targeted human protein therapeutics, today announced significant progress in validating novel, effective products for the potential treatment of asthma....

Halozyme Therapeutics' Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society

- Co-Injection of rHuPH20 with Humira Estimated to Increase the Maximal Steady State Subcutaneous Bioavailability from 64% to 100% - SAN DIEGO, July 09, 2007 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. , a biopharmaceutical company developing and commercializing recombinant human enzymes...

Near-Patient Testing: The Advantages of C-Reactive Protein in Hematological Testing

Professor Jean-Francois Rossi Medical Hematology and Oncology CHU Lapeyronie, Montpellier C-reactive protein (CRP) is an acute-phase protein that has long been recognized as a marker of systemic inflammation. CRP measurement can complement a range of diagnostic markers to monitor infect...

Study in Cell by Magen BioSciences Co-Founder David E. Fisher Identifies New Roles in Skin Cancer Prevention for Key Tumor Suppressor Protein

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar 8, 2007 - Magen BioSciences, Inc., a specialty dermatology company, today announced the publication of a paper in the March 9, 2007 issue of the journal Cell by its co-founder and board member, David E. Fisher, M.D., Ph.D., that identifies two new functions fo...

DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein

Top Line Data for the Treatment of Type 2 Diabetes Presented at the 67th Annual Scientific Sessions of American Diabetes Association SAN FRANCISCO, June 25, 2007 /PRNewswire/ -- DiObex, Inc., a privately-held biopharmaceutical company focused on the development of therapeutics to treat metabolic d...

Vectibix(R) in Combination With Chemotherapy Significantly Improved Progression-Free Survival in First-Line Metastatic Colorectal Cancer

...downstream events that lead to malignant signaling. However, it is hypothesized that in patients whose tumors harbor a mutated KRAS gene, the KRAS protein is always turned "on," regardless of whether the EGFR has been activated or therapeutically inhibited. KRAS mutations occur in approximately 40 - 50...

Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009

...y recently completed its Phase 1 study of LY2181308 and presented data confirming that LY2181308 penetrates tumor tissue and reduces survivin mRNA and protein levels in tumor cells. Isis and its collaborators highlighted new antisense therapeutic programs and targets to treat metabolic ...

Debiopharm Group and Mercury Therapeutics, Inc. Sign an Exclusive License Agreement for the Development and Commercialisation of Debio 0930

...usive license agreement for the development and commercialisation of Debio 0930, a small molecule activator of AMPK (adenosine monophosphate activated protein kinase) for the treatment of diabetes and metabolic diseases. Activation of AMPK has been shown to lower fasting blood glucose levels and improve gluc...

Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)

... of underlying cancer, the process by which cancers invade and destroy bones is fundamentally the same. At the center of this destructive process is a protein RANK Ligand that is stimulated by the presence of cancer in the bone. The economic burden of U.S. patients with bone metastases is significant...

OPAXIO(TM) Combined with Alimta(R) Well Tolerated in Dose-Ranging Study of Patients with Advanced Non-Small Cell Lung Cancer

...nificantly more of the dose of chemotherapy to localize in the tumor than with standard paclitaxel. Once inside the tumor cell, enzymes metabolize the protein polymer, releasing the paclitaxel chemotherapy. Preclinical and clinical studies support that OPAXIO metabolism by lung cancer cells may be influenced...

Video: New Dove(R) Body Washes with NutriumMoisture(TM) Restore Skin's Natural Moisture

... during cleansing which is critical for optimal skin health. The formulation is comprised of sodium lauroyl isethionate, a mild cleanser that reduces protein damage, and 100% skin-compatible natural moisturizers, including stearic acid, soybean oil and glycerin, that fully absorb into skin to replenish lipi...

R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent

...o see excellent results in the objective measures and in the Synovitis and Osteitis MRI scores," he added. *blood measurements of C-Reactive protein (CRP) and Erythrocyte Sedimentation Rate (ESR) Efficacy Results Treatment N of Pts ACR 20 ACR 50 ACR 70 DAS28&l...

Researchers Create First Targeted Knockout Rats Using Zinc Finger Nuclease Technology

...y including Dow AgroSciences, Sigma-Aldrich Corporation and several companies applying its ZFP technology to engineer cell lines for the production of protein pharmaceuticals. For more information about Sangamo, visit the company's web site at www.sangamo.com . About the Medical College of Wis...

Octapharma Accepting Applications for Research Grants on Immunotherapy, Coagulation Disorders and Critical Care

...clinical or pre-clinical research focused on human protein therapies in coagulation disorders, immunotherapy...ng patients with the safest, highest quality human protein therapies available is stronger than ever," said O...lopment, production and sale of high quality human protein therapies, including immune globulin intravenous...

National Cancer Institute Research Identifies Unique Mechanism of Brostallicin's Anti-Tumor Effectiveness

...tumors. Brostallicin was shown to affect DNA in both dividing and quiescent cells. Its actions can be followed by induction of a specific DNA binding protein foci that can be detected in circulating blood cells. Importantly, brostallicin was active in a trabectedin-resistant cell line. "These pre...

Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA(TM) in Systemic Lupus Erythematosus

... antibody drug that specifically recognizes and inhibits the biological activity of B-lymphocyte stimulator, or BLyS(R). BLyS is a naturally occurring protein discovered by HGS that is required for the development of B-lymphocyte cells into mature plasma B cells. Plasma B cells produce antibodies, the body's...

Cognition Therapeutics Closes Series A Financing to Advance Drug Candidates for Alzheimer's Disease

...the activity of the toxic oligomeric form of Abeta protein that interferes with normal learning and memory. ... that the memory deficits caused by the oligomeric protein are among the earliest changes seen in Alzheimer's...studies indicate that blocking the effects of this protein may halt or reverse Alzheimer's disease. Cognitio...

Results From Drug Trials and New Risk Factors Announced at International Alzheimer's Conference

... Alzheimer's. Phase III Alzheimer's Drug Raises Level of a Toxic protein Recent evidence suggests that the drug Dimebon may improve cogni..., known as beta amyloid, in animal models of Alzheimer's. Beta amyloid is a protein that is the main constituent of plaques found in the brains of people with ...

Michael J. Fox Foundation Awards Over $2 Million for Validation of 10 Parkinson's Therapeutic Targets

...MD, Ecole Polytechnique Federale de Lausanne (Switzerland) and Deniz Kirik, MD, PhD, Lund University (Sweden) Validation of cyclophilin D, a protein involved in the mitochondrial permeability transi tion, as a target for Parkinson' s disease therapy Mathieu Lesort, PhD, University of Alabama...

Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center

...renal disease. The Company is also developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that modulates Akt, a protein in the body associated with tumor survival and growth. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK a...

Fruitfly Model of a Neuropathic Disease Demonstrates Novel Role for Proteins in the Family of aTyr Pharma's Product Class

...for aTyr Pharma's new class of naturally occurring protein agents. The aminoacyl tRNA synthetases are universal and essential components of protein synthesis machinery found in all organisms, but hu...s with cell signaling activities distinct from the protein synthesis activities. In this recently published...

Sirius Genomics Announces New Collaboration with Assistance Publique-Hopitaux de Paris

... agreement focuses on the continued development of Sirius' pharmacogenomic diagnostic intended to assess responsiveness to recombinant human activated protein C (sold by Eli Lilly and Company under the trademark Xigris (R)) in patients with severe sepsis at high risk of death. "Access to AP-HP's severe sep...

Rigel's R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial

...rement factors include reported physician and patient global assessment of disease activity, patient reported pain score, and any change in C-reactive protein (CRP) in the patients' blood. The primary efficacy endpoint for the study was the percent of patients assigned to the R788 100 mg bid dose who were A...

Neuroscience Researcher Has Positive Message for International Alzheimer's Awareness Week, July 6 - 12: 'Even Though World Economy is Declining, Alzheimer's Research is Advancing'

...ations. "We asked 83 healthy volunteers with self-described poor memory to consume a supplement (Prevagen(R), www.prevagen.com ) containing a protein found in jellyfish that buffers calcium by binding to it," says Underwood. "After 90 days, 63% of the volunteers reported less forgetfulness, 8...

Pangu BioPharma, aTyr Pharma's Subsidiary in Hong Kong, Files Three Patent Applications

...application on proprietary, naturally occurring, resected human tRNA synthetases. Although tRNA synthetases are universal and essential components of protein synthesis machinery found in all organisms, human synthetases have naturally occurring resected variants with potent cell signaling activities that ar...